On December 6, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), reported that its WP1066 drug will receive $2 million in private grant funding for its recently announced Investigational New Drug ("IND") clearance for a physician-sponsored Phase I trial of Moleculin’s drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma (Press release, Moleculin, DEC 6, 2017, View Source [SID1234522405]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"On the heels of our recent IND announcement, we are honored to now announce that a significant private grant has been awarded to help cover the costs of the upcoming brain tumor trial at MD Anderson," commented Walter Klemp, Chairman and CEO of Moleculin. "We should emphasize that this $2 million grant is in addition to two prestigious SPORE grants awarded by the National Cancer Institute ("NCI")."

Mr. Klemp added, "The Specialized Programs of Research Excellence ("SPORE") program was established by NCI to enable the rapid and efficient movement of basic scientific findings into clinical settings and it is now considered a highly prestigious award for promising anticancer technologies. Due to the highly competitive nature of such grants and their and external review processes, we believe they provide further validation of our program and the approach to the treatment of brain cancer and cancer metastasis to the brain. Overall, the combination of all of these funding sources not only allows this trial to begin to move forward, we believe it signals strong support for the development of this class of potential drugs and more specifically, significant enthusiasm for the potential of WP1066 to shut down unwanted cell signaling and to empower the immune system to fight cancer."

The grants described here do not flow through Moleculin’s financial statements, but instead are applied to the cost of preclinical and clinical activities at and conducted by MD Anderson.

On December 6, 2017 Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that the company will increase the targeted patient enrollment in the relapsed/refractory (R/R) multiple myeloma (MM) cohort of its currently enrolling Phase 2 clinical trial of CLR 131. Data from the MM cohort of the study demonstrated that the treatment exceeded pre-specified criteria for clinically meaningful benefit (Press release, Cellectar Biosciences, DEC 6, 2017, View Source [SID1234522403]). As a result, the cohort will be expanded up to as many as 40 patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The initial results from the multiple myeloma arm of this Phase 2 study underscore the potential for CLR 131 to benefit these heavily pre-treated and relapsed patients. We continue to see clinical benefit with CLR 131 in both our Phase 1 and Phase 2 clinical studies and look forward to reporting additional data from the both of these clinical studies next year.," stated James Caruso, president and chief executive officer of Cellectar Biosciences. "Furthermore, we are pleased to have achieved this key clinical milestone within our projected timelines" added Mr. Caruso.

On December 6, 2017 Amgen (NASDAQ:AMGN) reported that it will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition on Saturday, Dec. 9, 2017, at 11:30 a.m. ET (Press release, Amgen, DEC 6, 2017, View Source;p=RssLanding&cat=news&id=2321467 [SID1234522402]). David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen, together with other members of Amgen’s management team and a clinical investigator, will participate to discuss the Company’s oncology program, including our BiTE immunotherapy platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live audio of the investor call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

On December 6, 2017 Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported a partnership with the University of California San Diego to develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies (Press release, Fate Therapeutics, DEC 6, 2017, View Source [SID1234522400]). The two-year collaboration is being led by Dan S. Kaufman, M.D., Ph.D., Professor of Medicine in the Division of Regenerative Medicine and Director of Cell Therapy at UC San Diego School of Medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NK cells have the inherent ability to target a diversity of stress-induced ligands on tumor cells and can be safely administered without the need for individualized patient matching. Additionally, NK cells engineered with chimeric antigen receptors can be targeted to tumors with high specificity. This duality provides CAR NK cells with the unique potential to overcome antigen escape and address tumor heterogeneity, which are distinct advantages over patient-specific CAR T-cell immunotherapies," said Dr. Kaufman. "We have now identified several CAR constructs optimized for NK cell signaling, persistence and cytotoxicity, and combined our targeting content with Fate Therapeutics’ induced pluripotent stem cell product platform for development of off-the-shelf CAR-targeted NK cell products using clonal engineered master pluripotent cell lines."

The CAR constructs identified by the collaborators contain transmembrane and co-stimulatory domains that enhance antigen-specific NK cell activation and improve the effector function of NK cells. Fate Therapeutics holds an exclusive license to the intellectual property covering these CAR constructs and maintains an option to exclusively license intellectual property arising from all research and development activities under the collaboration.

At the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, Dr. Kaufman and Fate Therapeutics will present preclinical data on Saturday, December 9, 2017 highlighting CAR-targeted NK cells derived from an induced pluripotent stem cell (iPSC) engineered with a specific CAR construct containing a NKG2D transmembrane domain, a 2B4 co-stimulatory domain and a CD3ζ signaling domain. In preclinical studies using an ovarian cancer xenograft model, the collaborators have shown that a single dose of CAR-targeted NK cells derived from iPSCs engineered with this specific CAR construct markedly inhibited tumor growth and significantly enhanced survival as compared to NK cells containing a CAR construct commonly used for T-cell immunotherapy. Dr. Kaufman was recently awarded $5.15 million by the California Institute for Regenerative Medicine (CIRM) to advance clinical translation of NK cells derived from pluripotent stem cells into a standardized treatment for treating hematologic malignancies.

iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The engineering of iPSCs can be done as a one-time genetic modification event and a single iPSC can be selected for creation of a clonal master pluripotent cell line. Similar to master cell lines used for the manufacture of therapeutic antibodies, a clonal master pluripotent cell line can be used to repeatedly create clonal populations of effector cells. This first-of-kind approach enables large-scale generation of off-the-shelf, targeted, homogeneous cell products that can be administered in repeat doses to mediate more effective pharmacologic activity, including in combination with cycles of other cancer treatments.

On December 6, 2017 Geron Corporation (Nasdaq:GERN) reported that the company’s analyst and investor meeting to discuss imetelstat clinical data will take place in New York, N.Y., on Tuesday, December 19, 2017 (Press release, Geron, DEC 6, 2017, View Source;p=RssLanding&cat=news&id=2321341 [SID1234522399]). The presentation will begin at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Azra Raza, M.D., Professor of Medicine and Director of the Myelodysplastic Syndromes (MDS) Center at New York-Presbyterian/Columbia University Medical Center in New York City, will present data from Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of the telomerase inhibitor imetelstat in patients with lower risk MDS being conducted by Janssen Research & Development, LLC. These data have been accepted as a poster presentation at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition.

A live audio webcast of the presentation will be available through the Investors section of Geron’s website (www.geron.com) under Events. Following the live presentation, the webcast will be archived and available for replay for a period of 30 days.

To attend the meeting in person, please send an email to Gitanjali Jain Ogawa at The Trout Group ([email protected]) for further information.